274 related articles for article (PubMed ID: 36805632)
1. Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes.
Pikkusaari S; Tumiati M; Virtanen A; Oikkonen J; Li Y; Perez-Villatoro F; Muranen T; Salko M; Huhtinen K; Kanerva A; Koskela H; Tapper J; Koivisto-Korander R; Joutsiniemi T; Haltia UM; Lassus H; Hautaniemi S; Färkkilä A; Hynninen J; Hietanen S; Carpén O; Kauppi L
Clin Cancer Res; 2023 Aug; 29(16):3110-3123. PubMed ID: 36805632
[TBL] [Abstract][Full Text] [Related]
2. Homologous recombination deficiency real-time clinical assays, ready or not?
Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
[TBL] [Abstract][Full Text] [Related]
3. Clinical assays for assessment of homologous recombination DNA repair deficiency.
Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
[TBL] [Abstract][Full Text] [Related]
4. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
[TBL] [Abstract][Full Text] [Related]
5. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
Miller RE; Leary A; Scott CL; Serra V; Lord CJ; Bowtell D; Chang DK; Garsed DW; Jonkers J; Ledermann JA; Nik-Zainal S; Ray-Coquard I; Shah SP; Matias-Guiu X; Swisher EM; Yates LR
Ann Oncol; 2020 Dec; 31(12):1606-1622. PubMed ID: 33004253
[TBL] [Abstract][Full Text] [Related]
6. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
[TBL] [Abstract][Full Text] [Related]
7. A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
Tumiati M; Hietanen S; Hynninen J; Pietilä E; Färkkilä A; Kaipio K; Roering P; Huhtinen K; Alkodsi A; Li Y; Lehtonen R; Erkan EP; Tuominen MM; Lehti K; Hautaniemi SK; Vähärautio A; Grénman S; Carpén O; Kauppi L
Clin Cancer Res; 2018 Sep; 24(18):4482-4493. PubMed ID: 29858219
[No Abstract] [Full Text] [Related]
8. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival.
Mukhopadhyay A; Plummer ER; Elattar A; Soohoo S; Uzir B; Quinn JE; McCluggage WG; Maxwell P; Aneke H; Curtin NJ; Edmondson RJ
Cancer Res; 2012 Nov; 72(22):5675-82. PubMed ID: 23066035
[TBL] [Abstract][Full Text] [Related]
10. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
Swisher EM; Aghajanian C; O'Malley DM; Fleming GF; Kaufmann SH; Levine DA; Birrer MJ; Moore KN; Spirtos NM; Shahin MS; Reid TJ; Friedlander M; Steffensen KD; Okamoto A; Sehgal V; Ansell PJ; Dinh MH; Bookman MA; Coleman RL
Gynecol Oncol; 2022 Feb; 164(2):245-253. PubMed ID: 34906376
[TBL] [Abstract][Full Text] [Related]
11. Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
Pellegrino B; Herencia-Ropero A; Llop-Guevara A; Pedretti F; Moles-Fernández A; Viaplana C; Villacampa G; Guzmán M; Rodríguez O; Grueso J; Jiménez J; Arenas EJ; Degasperi A; Dias JML; Forment JV; O'Connor MJ; Déas O; Cairo S; Zhou Y; Musolino A; Caldas C; Nik-Zainal S; Clarke RB; Nuciforo P; Díez O; Serres-Créixams X; Peg V; Espinosa-Bravo M; Macarulla T; Oaknin A; Mateo J; Arribas J; Dienstmann R; Bellet M; Oliveira M; Saura C; Gutiérrez-Enríquez S; Balmaña J; Serra V
Cancer Res; 2022 Apr; 82(8):1646-1657. PubMed ID: 35425960
[TBL] [Abstract][Full Text] [Related]
12. Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
Wen H; Feng Z; Ma Y; Liu R; Ou Q; Guo Q; Shen Y; Wu X; Shao Y; Bao H; Wu X
BMC Cancer; 2022 May; 22(1):550. PubMed ID: 35578198
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis of Ovarian Carcinoma Homologous Recombination DNA Repair Deficiency From Targeted Gene Capture Oncology Assays.
Krumm N; Khasnavis NS; Radke M; Banda K; Davies HR; Pennil C; McLean K; Paulson VA; Konnick EQ; Johnson WC; Huff G; Nik-Zainal S; Swisher EM; Lockwood CM; Salipante SJ
JCO Precis Oncol; 2023 May; 7():e2200720. PubMed ID: 37196218
[TBL] [Abstract][Full Text] [Related]
14. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
Ngoi NYL; Tan DSP
ESMO Open; 2021 Jun; 6(3):100144. PubMed ID: 34015643
[TBL] [Abstract][Full Text] [Related]
15. Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.
Paulet L; Trecourt A; Leary A; Peron J; Descotes F; Devouassoux-Shisheboran M; Leroy K; You B; Lopez J
Eur J Cancer; 2022 May; 166():87-99. PubMed ID: 35279473
[TBL] [Abstract][Full Text] [Related]
16. Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials.
Purwar R; Ranjan R; Pal M; Upadhyay SK; Kumar T; Pandey M
World J Surg Oncol; 2023 May; 21(1):157. PubMed ID: 37217940
[TBL] [Abstract][Full Text] [Related]
17. Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
Gourley C; Miller RE; Hollis RL; Ledermann JA
Curr Opin Oncol; 2020 Sep; 32(5):442-450. PubMed ID: 32796232
[TBL] [Abstract][Full Text] [Related]
18. A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.
Blanc-Durand F; Yaniz-Galende E; Llop-Guevara A; Genestie C; Serra V; Herencia-Ropero A; Klein C; Berton D; Lortholary A; Dohollou N; Desauw C; Fabbro M; Malaurie E; Bonichon-Lamaichhane N; Dubot C; Kurtz JE; de Rauglaudre G; Raban N; Chevalier-Place A; Ferron G; Kaminsky MC; Kramer C; Rouleau E; Leary A
Gynecol Oncol; 2023 Apr; 171():106-113. PubMed ID: 36868112
[TBL] [Abstract][Full Text] [Related]
19. Performance of a RAD51-based functional HRD test on paraffin-embedded breast cancer tissue.
van Wijk LM; Vermeulen S; Ter Haar NT; Kramer CJH; Terlouw D; Vrieling H; Cohen D; Vreeswijk MPG
Breast Cancer Res Treat; 2023 Dec; 202(3):607-616. PubMed ID: 37725154
[TBL] [Abstract][Full Text] [Related]
20. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]